| Report ID | 273126 |
| Drug Identification Number | 02241357 |
| Brand name | IFEX |
| Common or Proper name | Ifosfamide |
| Company Name | BAXTER CORPORATION |
| Market Status | MARKETED |
| Active Ingredient(s) | IFOSFAMIDE |
| Strength(s) | 1G |
| Dosage form(s) | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 1000 mg |
| ATC code | L01AA |
| ATC description | ALKYLATINGAGENTS |
| Reason for shortage | Shortage of an active ingredient. |
| Anticipated start date | 2025-12-19 |
| Actual start date | 2025-12-19 |
| Estimated end date | 2026-05-01 |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2026-01-19 |
| Company comments | Ifex (1g) is currently on 50% allocation. Foreign-labelled product (3g) has been approved for import. Once imported and ready to be released, foreign-labelled Ifex (3g) will be available for purchase. |
| Health Canada comments | |
| Tier 3 Status | Yes |
| Contact Address | 7125 MISSISSAUGA ROAD MISSISSAUGA, ONTARIO CANADA L5N 0C2 |
| Company contact information |
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v7 | 2026-01-19 | French | Compare |
| v6 | 2026-01-19 | English | Compare |
| v5 | 2025-12-22 | English | Compare |
| v4 | 2025-12-18 | French | Compare |
| v3 | 2025-12-18 | English | Compare |
| v2 | 2025-12-03 | French | Compare |
| v1 | 2025-12-03 | English | Compare |
Showing 1 to 7 of 7